Indirubin derivatives as potent FLT3 inhibitors with anti-proliferative activity of acute myeloid leukemic cells

被引:33
作者
Choi, Soo Jeong [1 ]
Moon, Myoung Ju [1 ]
Lee, So Deok [1 ]
Choi, Sang-Un [2 ]
Han, Sun-Young [2 ]
Kim, Yong-Chul [1 ]
机构
[1] Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea
[2] Korea Res Inst Chem Technol, Pharmacol Res Ctr, Taejon 305600, South Korea
关键词
Indirubin; FLT3; kinase; Acute myeloid leukemic cells; Cell cycle; RECEPTOR TYROSINE KINASE; CLINICAL-SIGNIFICANCE; WILD-TYPE; MALIGNANCIES; ACTIVATION; PKC412; AML;
D O I
10.1016/j.bmcl.2010.01.039
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Indirubin derivatives were identified as potent FLT3 tyrosine kinase inhibitors with anti-proliferative activity at acute myeloid leukemic cell lines, RS4; 11 and MV4; 11 which express FLT3-WT and FLT3-ITD mutation, respectively. Among several 5 and 5'-substituted indirubin derivatives, 5-fluoro analog, 13 exhibited potent inhibitory activity at FLT3 (IC50 = 15 nM) with more than 100-fold selectivity versus 6 other kinases and potent anti-proliferative effect for MV4; 11 cells (IC50 = 72 nM) with 30-fold selectivity versus RS4; 11 cells. Cell cycle analysis indicated that compound 13 induced cell cycle arrest at G(0)/G(1) phase in MV4; 11 cells. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2033 / 2037
页数:5
相关论文
共 16 条
[1]   FLT3 and acute myelogenous leukemia: Biology, clinical significance and therapeutic applications [J].
Advani, AS .
CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (26) :3449-3457
[2]   Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor [J].
Dai, Yujia ;
Hartandi, Kresna ;
Ji, Zhiqin ;
Ahmed, Asma A. ;
Albert, Daniel H. ;
Bauch, Joy L. ;
Bouska, Jennifer J. ;
Bousquet, Peter F. ;
Cunha, George A. ;
Glaser, Keith B. ;
Harris, Christopher M. ;
Hickman, Dean ;
Guo, Jun ;
Li, Junling ;
Marcotte, Patrick A. ;
Marsh, Kennan C. ;
Moskey, Maria D. ;
Martin, Ruth L. ;
Olson, Amanda M. ;
Osterling, Donald J. ;
Pease, Lori J. ;
Soni, Niru B. ;
Stewart, Kent D. ;
Stoll, Vincent S. ;
Tapang, Paul ;
Reuter, David R. ;
Davidsen, Steven K. ;
Michaelides, Michael R. .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (07) :1584-1597
[3]   Role of FLT3 in leukemia [J].
Gilliland, DG ;
Griffin, JD .
CURRENT OPINION IN HEMATOLOGY, 2002, 9 (04) :274-281
[4]   The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases [J].
Knapper, Steven ;
Mills, Kenneth I. ;
Gilkes, Amanda F. ;
Austin, Steve J. ;
Walsh, Val ;
Burnett, Alan K. .
BLOOD, 2006, 108 (10) :3494-3503
[5]  
Kottaridis PD, 2003, BRIT J HAEMATOL, V122, P523
[6]   FLT3: ITDoes matter in leukemia [J].
Levis, M ;
Small, D .
LEUKEMIA, 2003, 17 (09) :1738-1752
[7]   The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia [J].
Mollgard, Lars ;
Deneberg, Stefan ;
Nahi, Hareth ;
Bengtzen, Sofia ;
Jonsson-Videsater, Kerstin ;
Fioretos, Thoas ;
Andersson, Anna ;
Paul, Christer ;
Lehmann, Soren .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (03) :439-448
[8]   Synthesis and structure-activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities [J].
Moon, MJ ;
Lee, SK ;
Lee, JW ;
Song, WK ;
Kim, SW ;
Kim, JI ;
Cho, C ;
Choi, SJ ;
Kim, YC .
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (01) :237-246
[9]   Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia [J].
Ozeki, K ;
Kiyoi, H ;
Hirose, Y ;
Iwai, M ;
Ninomiya, M ;
Kodera, Y ;
Miyawaki, S ;
Kuriyama, K ;
Shimazaki, C ;
Akiyama, H ;
Nishimura, M ;
Motoji, T ;
Shinagawa, K ;
Takeshita, A ;
Ueda, R ;
Ohno, R ;
Emi, N ;
Naoe, T .
BLOOD, 2004, 103 (05) :1901-1908
[10]   Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family [J].
Pandey, A ;
Volkots, DL ;
Seroogy, JM ;
Rose, JW ;
Yu, JC ;
Lambing, JL ;
Hutchaleelaha, A ;
Hollenbach, SJ ;
Abe, K ;
Giese, NA ;
Scarborough, RM .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (17) :3772-3793